Clinical Research Directory
Browse clinical research sites, groups, and studies.
MT2022-01: MSCs for ALD
Sponsor: Masonic Cancer Center, University of Minnesota
Summary
This is a single-institution study to evaluate the use of intravenously administered allogeneic, 3rd party mesenchymal stem cells (IV-MSC) in patients with active, cerebral adrenoleukodystrophy (CALD), as a bridge to hematopoietic stem cell transplant or gene therapy, or in patients who are too advanced for gene therapy or HSCT. The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks.
Official title: Intravenous Administration of Mesenchymal Stem Cells (IV-MSC) for the Treatment of Cerebral Adrenoleukodystrophy (cALD)
Key Details
Gender
All
Age Range
3 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2023-08-28
Completion Date
2029-05-01
Last Updated
2026-06-18
Healthy Volunteers
No
Conditions
Interventions
Mesenchymal stem cells (IV-MSC)
Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.
Locations (1)
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States